Wall Street brokerages expect Humanigen, Inc. (NASDAQ:HGEN – Get Rating) to report ($0.34) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Humanigen’s earnings, with estimates ranging from ($0.48) to ($0.22). Humanigen reported earnings per share of ($1.20) during the same quarter last year, which would indicate a positive year over year growth rate of 71.7%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Humanigen will report full year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($1.33) to $0.05. For the next year, analysts anticipate that the business will report earnings of $0.46 per share, with EPS estimates ranging from ($0.53) to $1.38. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Humanigen.
Humanigen (NASDAQ:HGEN – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.17. Humanigen had a negative return on equity of 24,421.51% and a negative net margin of 4,640.77%. The firm had revenue of $1.04 million for the quarter, compared to analysts’ expectations of $1.04 million.
Shares of NASDAQ HGEN traded up $0.02 during trading on Friday, reaching $2.26. 1,719,747 shares of the stock traded hands, compared to its average volume of 1,341,578. Humanigen has a 52-week low of $1.67 and a 52-week high of $23.53. The company has a 50-day moving average of $2.58 and a 200-day moving average of $3.37. The stock has a market capitalization of $159.62 million, a P/E ratio of -0.71 and a beta of -1.01.
In other Humanigen news, insider Dale Chappell bought 1,000,000 shares of the firm’s stock in a transaction on Friday, March 11th. The shares were acquired at an average cost of $3.00 per share, for a total transaction of $3,000,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Edward P. Jordan bought 12,500 shares of the firm’s stock in a transaction on Wednesday, March 2nd. The stock was acquired at an average price of $2.32 per share, for a total transaction of $29,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 1,778,688 shares of company stock worth $4,697,200. 21.70% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC increased its position in shares of Humanigen by 71.3% during the 1st quarter. Virtu Financial LLC now owns 37,463 shares of the company’s stock valued at $113,000 after purchasing an additional 15,588 shares during the last quarter. State Street Corp boosted its holdings in Humanigen by 31.7% during the 1st quarter. State Street Corp now owns 1,246,922 shares of the company’s stock valued at $3,753,000 after acquiring an additional 300,345 shares during the period. Frontier Wealth Management LLC purchased a new stake in Humanigen during the 1st quarter valued at about $155,000. XTX Topco Ltd purchased a new stake in Humanigen during the 1st quarter valued at about $111,000. Finally, BlackRock Inc. boosted its holdings in Humanigen by 0.7% during the 1st quarter. BlackRock Inc. now owns 3,367,015 shares of the company’s stock valued at $10,136,000 after acquiring an additional 23,215 shares during the period. Hedge funds and other institutional investors own 64.34% of the company’s stock.
Humanigen Company Profile (Get Rating)
Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia.
- Get a free copy of the StockNews.com research report on Humanigen (HGEN)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.